Our News

Feb 20, 2024 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This milestone marks a pivotal expansion in the company’s ability to serve patients and healthcare providers across California, the most populous state in the U.S.

Oct 20, 2024 | BALTIMORE – Complete Omics Inc., a trailblazer in clinical proteomics and multi-omics molecular diagnostics, is proud to announce its recent achievement of CLIA and CAP certifications, along with enrollment in the Medicare system. These accomplishments underscore Complete Omics’ unwavering commitment to providing top-tier diagnostic solutions, grounded in excellence and reliability, and advancing patient care through accessible, state-of-the-art clinical proteomics testing services.

August 20, 2024 | BALTIMORE –  Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are embarking on a groundbreaking collaboration set to redefine the landscape of single-cell multi-omics. By merging their cutting-edge technologies, this dynamic alliance is poised to revolutionize disease research and precision medicine, pushing the boundaries of what’s possible in healthcare innovation.

May 12, 2024 | BALTIMORE –  Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous three-year review by the USPTO. This breakthrough makes Valid-NEO® the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces. This milestone underscores the platform’s significant technical value, setting it apart in the neoantigen detection field.

January 12, 2024 | BALTIMORE –  Complete Omics’ Clinical Proteomics team are thrilled to announce that Dr. Hui Zhang, a distinguished figure in the realm of proteomics, has joined the Complete Omics family as our Chief Scientific Officer (CSO) and Director for the Center for Advanced Proteomics. Dr. Zhang, a founding member of the Clinical Proteomic Tumor Analysis Consortium (CPTAC), brings to our team a rich legacy of innovation and leadership in proteomics, especially known for her pioneering work in multi-omics studies on human cancers and her revolutionary innovation on the methods in studying N-Glycosylation on proteins.

November 25, 2023 | BALTIMORE –  Complete Omics management team are thrilled to announce a significant milestone for our company – a recent investment by Qiming Venture Partners. This partnership marks a pivotal moment in our journey, as we continue to advance our clinical proteomics platform and molecular diagnostics platform development. With this investment, we are poised to accelerate our efforts in bringing innovative solutions to the healthcare industry, ultimately aiming to improve patient outcomes through cutting-edge diagnostics.